Hanife Yılmaz ÇENGEL, Müge BOZKURT, Cüneyt EVREN

The severity of non-planning impulsivity and cannabis use problems in distinguishing patients with synthetic cannabinoid use disorder and cannabis use disorder

Objective: The present study aims to identify whether there is a difference between the synthetic cannabinoid (SC) and cannabis use disorder groups in terms of impulsivity and problems arising from substance use, as well as to determine the variables that distinguish SC use disorder cases from cannabis use disorder. Method: Fifty-two male patients with SC and 45 male patients with cannabis use disorder who were admitted to the AMATEM clinic of Bakirkoy Mental and Neurological Diseases Training and Research Hospital were included in the study. The participants were evaluated using the Barrat Impulsiveness Scale (BIS-11), Cannabis Use Problems Identification Test (CUPIT), Adult Cannabis Problems Questionnaire (CPQ), and Cannabis Withdrawal Scale (CWS). Results: The SC use disorder group had higher rates of unemployment, suicide, and self-mutilation than the cannabis use disorder group. The SC use disorder group scored significantly higher than those with cannabis use disorder in BIS-11, CUPIT, CPQ total score and sub-scale scores, and CWS score. Conclusion: It was shown in our study that cases with SC use disorder had a higher risk of impulsivity and problematic substance use than those with cannabis use disorder, and the CUPIT-B and non-planning impulsiveness sub-scales were also predictors of SC use disorder.

PDF

___

1. Hall WD, Lynskey M. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev 2005; 24:39-48.

2. Copeland J, Pokorski I. Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review. Subst Abuse Rehabil 2016; 7:41-53.

3. Evren C, Yilmaz Cengel H, Bozkurt M, Evren B, Umut G, Agachanli R. Psychometric properties of the Turkish versions of the Cannabis Use Problems Identification Test (CUPIT) and the adult Cannabis Problems Questionnaire (CPQ). J Psychoactive Drugs 2017; 49:83-89.

4. Evren C, Bozkurt M. Synthetic cannabinoids: crisis of the decade. Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2013; 26:1-11.

5. Dresen S, Ferreirós N, Pütz M, Westphal F, Zimmermann R, Auwärter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 2010; 45:1186-1194.

6. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). New psychoactive substances in Europe: An update from the EU Early Warning System. https://www.emcdda.europa. eu/system/files/publications/65/TD0415135ENN.pdf. Accesed October 31, 2020.

7. Gurdal F, Asirdizer M, Aker RG, Korkut S, Gocer Y, Kucukibrahimoglu EE, et al. Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey. J Forensic Leg Med 2013; 20:667-672.

8. Schneir AB, Cullen J, Ly BT. “Spice” girls: synthetic cannabinoid intoxication. J Emerg Med 2011; 40:296-299.

9. Vardakou I, Pistos C, Spiliopoulou Ch. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010; 197:157-162.

10. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014; 144:12-41.

11. Demirakca T, Sartorius A, Ende G, Meyer N, Welzel H, Skopp G, et al. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend 2011; 114:242-245.

12. Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med 2012; 60:435-438.

13. Perry JL, Carroll ME. The role of impulsive behavior in drug abuse. Psychopharmacology (Berl) 2008; 200:1-26.

14. de Wit H. Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addict Biol 2009; 14:22-31.

15. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol 1995; 51:768-774.

16. Cengel HY, Bozkurt M, Evren C, Umut G, Keskinkilic C, Agachanli R. Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder. Psychiatry Res 2018; 262:46-54.

17. Gulec H, Tamam L, Gulec MY, Turhan M, Karakus G, Zengin M, Stanford MS. Psychometric Properties of the Turkish Version of the Barratt. Bull Clin Psychopharmacol 2008; 18:251-258.

18. Bashford J, Flett R, Copeland J. The Cannabis Use Problems Identification Test (CUPIT): development, reliability, concurrent and predictive validity among adolescents and adults. Addiction 2010; 105:615-625.

19. Drummond DC. The relationship between alcohol dependence and alcohol-related problems in a clinical population. Br J Addict 1990; 85:357-366.

20. Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend 2011; 119:123-129.

21. Bozkurt M, Umut G, Evren C, Karabulut V. Clinical characteristics and laboratory test results of patients admitted to outpatient clinic for synthetic cannabinoid usage brief report. Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2014; 27:328.

22. Reinhard MA, Dewald-Kaufmann J, Wüstenberg T, Musil R, Barton BB, Jobst A, et al. The vicious circle of social exclusion and psychopathology: a systematic review of experimental ostracism research in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci 2020; 270:521-532.

23. Fattore L. Synthetic Cannabinoids-further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatry 2016; 79:539-548.

24. Patton AL, Chimalakonda KC, Moran CL, McCain KR, Radominska-Pandya A, James LP, et al. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci 2013; 58:1676-1680.

25. Waugh J, Najafi J, Hawkins L, Hill SL, Eddleston M, Vale JA, et al. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service. Clin Toxicol (Phila) 2016; 54:512-518.

26. Oliveira PMDS, Morais ASF, Madeira NGGF. Synthetic Cannabis Analogues and Suicidal Behavior: Case Report. J Addict Med 2017; 11:408-410.

27. Bassir Nia A, Medrano B, Perkel C, Galynker I, Hurd YL. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. J Psychopharmacol 2016; 30:1321- 1330.

28. Clayton HB, Lowry R, Ashley C, Wolkin A, Grant AM. Health risk behaviors with synthetic cannabinoids versus marijuana. Pediatrics 2017; 139:e20162675.

29. Oznur T, Oznur H, Bolu A, Atik S, Akgun A, Kaymak S, et al. Relationship between suicide attempts and synthetic cannabinoids in adjustment disorder. Dusunen Adam J Psychiatry Neurol Sci 2018; 31:258-264.

30. Kamijo Y, Takai M, Fujita Y, Hirose Y, Iwasaki Y, Ishihara S, et al. A multicenter retrospective survey of poisoning after consumption of products containing synthetic chemicals in Japan. Intern Med 2014; 53:2439-2445.

31. Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand 2011; 124:250- 261.

32. Carli V, Jovanović N, Podlesek A, Roy A, Rihmer Z, Maggi S, et al. The role of impulsivity in self-mutilators, suicide ideators and suicide attempters - a study of 1265 male incarcerated individuals. J Affect Disord 2010; 123:116-122.

33. Ergelen M, Yalçın M, Bilici R. The comparison of violence, and the relationship with childhood trauma in Turkish men with alcohol, opiate, and synthetic cannabinoid use disorder. Neuropsychiatr Dis Treat 2018; 14:3169-3178.

34. Perry JL, Carroll ME. The role of impulsive behavior in drug abuse. Psychopharmacology (Berl) 2008; 200:1-26.

35. Cohen K, Kapitány-Fövény M, Mama Y, Arieli M, Rosca P, Demetrovics Z, et al. The effects of synthetic cannabinoids on executive function. Psychopharmacology (Berl) 2017; 234:1121- 1134.

36. Verdejo-García A, Lawrence AJ, Clark L. Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev 2008; 32:777-810.

37. Ramírez JM, Andreu JM. Aggression, and some related psychological constructs (anger, hostility, and impulsivity); some comments from a research project. Neurosci Biobehav Rev 2006; 30:276-291.

38. Dick DM, Smith G, Olausson P, Mitchell SH, Leeman RF, O’Malley SS, et al. Understanding the construct of impulsivity and its relationship to alcohol use disorders. Addict Biol 2010; 15:217-226.

39. Bozkurt M, Evren C, Yilmaz A, Can Y, Cetingok S. Aggression and impulsivity in different groups of alcohol and heroin dependent inpatient men. Bulletin Clin Psychopharmacol 2013; 23:335-344.